Serum MMP-8, -9 and TIMP-1 in sepsis: High serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines

Pharmacological Research

Volumn 64, Issue 6, 2011, Pages 590-594

  Lauhio, Anneli ^a,b   Hästbacka, Johanna ^a   Pettilä, Ville ^a   Tervahartiala, Taina ^a,b   Karlsson, Sari ^c   Varpula, Tero ^a   Varpula, Marjut ^a   Ruokonen, Esko ^d   Sorsa, Timo ^a,b   Kolho, Elina ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Critical illness; Doxycycline; Immunoassays; MMP inhibitor; MMPs; Sepsis; Serum

Indexed keywords

GELATINASE B; NEUTROPHIL COLLAGENASE; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; COHORT ANALYSIS; CRITICAL ILLNESS; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATALITY; FEMALE; HUMAN; IMMUNE RESPONSE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; UPREGULATION;

ADULT; FEMALE; FINLAND; HUMANS; INTENSIVE CARE UNITS; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC; TETRACYCLINES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 80054091646     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.06.019     Document Type: Article

References (36)

1. S. Karlsson, M. Varpula, E. Ruokonen, V. Pettilä, I. Parviainen, and T.I. Ala-Kokko Incidence, treatment and outcome of severe sepsis in ICU-treated adults in Finland, the Finnsepsis study Intensive Care Med 33 2007 435 443 (Pubitemid 46333839)
2. J. Cena, M.M. Lalu, C. Rosenfelt, and R. Schulz Endothelial dependence of matrix metalloproteinase-mediated vascular hyporeactivity caused by lipopolysaccharide Eur J Pharmacol 582 2008 116 122
3. E.K. Robinson, C.M. Seaworth, J.W. Suliburk, S.D. Adams, L.S. Kao, and D.W. Mercer Effect of NOS inhibition on rat gastric matrix metalloproteinase production during endotoxemia Shock 25 2006 507 514
4. I. Vanlaere, and C. Libert Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock Clin Microbiol Rev 22 2009 224 239
5. T. Sorsa, L. Tjäderhane, and Y.T. Konttinen Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation Ann Med 38 2006 306 321 (Pubitemid 44385100)
6. C.A. Owen, Z. Hu, C. Lopez-Otin, and S.D. Shapiro Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase J Immunol 172 2004 7791 7803 (Pubitemid 38747647)
7. M.M. Gueders, M. Balbin, N. Rocks, J.M. Foidart, P. Gosset, and R. Louis Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation J Immunol 175 2005 2589 2597 (Pubitemid 41113872)
8. J.T. Korpi, V. Kervinen, H. Mäklin, A. Väänänen, M. Lahtinen, and E. Läärä Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer Br J Cancer 98 2008 766 775 (Pubitemid 351272624)
9. H. Kuula, T. Salo, E. Pirilä, A.M. Tuomainen, M. Jauhiainen, and V.J. Uitto Local and systemic responses in matrix metalloproteinase 8-deficient mice during Porphyromonas gingivalis-induced periodontitis Infect Immun 77 2009 850 859
10. P. Piirilä, A. Lauhio, M.L. Majuri, A. Meuronen, M. Myllärniemi, and T. Tervahartiala Matrix metalloproteinases-7, -8, -9 and TIMP-1 in the follow-up of diisocyanate-induced asthma Allergy 65 2009 61 68
11. G.A. McQuibban, J.H. Gong, E.M. Tam, C.A. McCulloch, I. Clark-Lewis, and C.M. Overall Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3 Science 289 2000 1202 1206 (Pubitemid 30650734)
12. J.J. Cena, M.M. Lalu, W.J. Cho, A.K. Chow, M.L. Bagdan, and E.E. Daniel Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia Am J Physiol Heart Circ Physiol 298 2010 1145 1151
13. A. Lauhio, Y.T. Konttinen, T. Salo, H. Tschesche, J. Lähdevirta, and F. Woessner Jr. Placebo-controlled study of the effects of three-month lymecycline treatment on serum matrix metalloproteinases in reactive arthritis Ann NY Acad Sci 732 1994 424 426
14. B. Dubois, S. Starckx, A. Pagenstecher, J. Oord, B. Arnold, and G. Opdenakker Gelatinase B deficiency protects against endotoxin shock Eur J Immunol 2 2002 163 171
15. S.R. Maitra, S. Bhaduri, P.D. Valane, T. Tervahartiala, T. Sorsa, and N. Ramamurthy Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis Shock 20 2003 280 285
16. J. Hu, P.E. Van den Steen, C. Dillen, and G. Opdenakker Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock Biochem Pharmacol 70 2005 535 544 (Pubitemid 40978543)
17. J. Hu, V. Dubois, P. Chaltin, P. Fiten, C. Dillen, and P.E. Van den Steen Inhibition of lethal endotoxin shock with an l-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library Comb Chem High Throughput Screen 9 2006 599 611 (Pubitemid 44320409)
18. J. Steinberg, J. Halter, H. Schiller, L. Gatto, D. Carney, and H.M. Lee Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model Shock 24 2005 348 356 (Pubitemid 41416521)
19. M.M. Lalu, J. Cena, R. Chowdhury, A. Lam, and R. Schulz Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction Br J Pharmacol 149 2006 31 42 (Pubitemid 44299066)
20. U. Hoffmann, T. Bertsch, E. Dvortsak, C. Liebetrau, S. Lang, and V. Liebe Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis Scand J Infect Dis 38 2006 867 872 (Pubitemid 44489515)
21. L. Lorente, M.M. Martín, L. Labarta, C. Díaz, J. Solé-Violán, and J. Blanquer Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis Crit Care 13 2009 R158
22. J. Hästbacka, M. Hynninen, E. Kolho, V. Pettilä, T. Tervahartiala, and T. Sorsa Collagenase 2/matrix metalloproteinase 8 in critically ill patients with secondary peritonitis Shock 27 2007 145 150 (Pubitemid 46105830)
23. F.P. Gäddnäs, M.M. Sutinen, M. Koskela, T. Tervahartiala, T. Sorsa, and T.A. Salo Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis Crit Care 14 2010 R49
24. R.C. Bone, R.A. Balk, F.B. Cerra, R.P. Dellinger, A.M. Fein, and W.A. Knaus Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis Chest 101 1992 1644 1655
25. H.I. Rautelin, A.M. Oksanen, L.I. Veijola, P.I. Sipponen, T.I. Tervahartiala, and T.A. Sorsa Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis Ann Med 41 2009 208 215
26. P. Van Lint, and C. Libert Matrix metalloproteinase-8: cleavage can be decisive Cytokine Growth Factor Rev 17 2006 217 223 (Pubitemid 44038613)
27. A.M. Tuomainen, K. Nyyssönen, J.A. Laukkanen, T. Tervahartiala, T.P. Tuomainen, and J.T. Salonen Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men Arterioscler Thromb Vasc Biol 27 2007 2722 2728 (Pubitemid 350158928)
28. T. Sorsa, M. Hernandez, J. Leppilahti, S. Munjal, L. Lutz Netuschil, and P. Mäntylä Detection of gingival crevicular fluid MMP-8 levels with different laboratory and chair-side methods Oral Dis 16 2010 39 45
29. T. Sorsa, T. Tervahartiala, J. Leppilahti, M. Hernandez, J. Gamonal, and A.M. Tuomainen Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines Pharmacol Res 63 2011 108 113
30. A. Lauhio, T. Sorsa, O. Lindy, K. Suomalainen, H. Saari, and L.M. Golub The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis Arthritis Rheum 35 1992 195 198
31. A. Lauhio, T. Salo, Y. Ding, Y.T. Konttinen, D. Nordström, and H. Tschesche In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis Clin Exp Immunol 98 1994 21 28 (Pubitemid 24315446)
32. A. Lauhio, Y.T. Konttinen, H. Tschesche, D. Nordström, T. Salo, and J. Lähdevirta Reduction of matrix metalloproteinase 8-neutrophil collagenase levels during long-term doxycycline treatment of reactive arthritis Antimicrob Agents Chemother 38 1994 400 402 (Pubitemid 24054275)
33. L.M. Golub, H.M. Lee, J.A. Stoner, T. Sorsa, R.A. Reinhardt, and M.S. Wolff Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women J Periodontol 79 2008 1409 1418
34. L.M. Golub, H.M. Lee, M.E. Ryan, W.V. Giannobile, J. Payne, and T. Sorsa Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms Adv Dent Res 12 1998 12 26
35. A. Lauhio, P. Saikku, T. Salo, H. Tschesche, J. Lähdevirta, and T. Sorsa Combination treatment in Chlamydia-triggered reactive arthritis. Comment on the article by Carter et al. Arthritis Rheum 63 2011 305 307
36. Roy SK, Kendrik D, Nieman G, Gatto L, Sadowitz B, Snyder K, Jack of all trades: pleotrophy and the application of chemically modified tetracycline-3 in sepsis and acute respiratory distress syndrome. Pharmacol Res; this issue.